Oramorph (Morphine Sulfate Pentahydrate)

Morphine Sulfate, the active ingredient in Oramorph, is an opioid analgesic presented as an oral formulation for systemic use. It is employed to manage moderate to severe pain in adult patients when alternative treatments are inadequate.

GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oramorph is an opioid analgesic that acts within the central nervous system to relieve pain across several clinical situations. - Acute postoperative pain: Provides effective relief following surgical procedures. - Cancer‑related pain: Helps control persistent pain associated with malignant disease. - Severe chronic pain: Used when long‑term opioid therapy is indicated for conditions such as advanced osteoarthritis or neuropathic pain.

Adverse reactions to morphine may vary in frequency and severity.

Common Side Effects: - Constipation: Reduced gastrointestinal motility. - Nausea and vomiting: Stimulation of the chemoreceptor trigger zone. - Drowsiness: Central nervous system depression. - Dry mouth: Decreased salivary secretion. - Pruritus: Histamine release causing skin itching. - Urinary retention: Decreased detrusor muscle activity.

Serious or Rare Side Effects: - Respiratory depression: Reduced drive to breathe, potentially life‑threatening. - Severe hypotension: Marked drop in blood pressure. - Opioid dependence or addiction: Development of physical or psychological reliance. - Adrenal insufficiency: Suppression of the hypothalamic‑pituitary‑adrenal axis. - Anaphylaxis: Immediate hypersensitivity reaction. - Neurotoxicity: Rare central nervous system toxicity with high doses.

When prescribing Oramorph, clinicians should evaluate patient‑specific factors and monitor for safety concerns. - Assess renal and hepatic function: Adjust dosing in impairment. - Evaluate respiratory status: Avoid use in patients with significant respiratory depression. - Review concomitant CNS depressants: Increased risk of sedation and respiratory depression. - Monitor for signs of dependence: Counsel patients on proper use. - Pregnancy and lactation: Weigh benefits against potential fetal or neonatal risk. - Store at ambient temperature: Keep below 25°C in the original container, protected from moisture and light.

Morphine may interact with a range of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: Combined CNS depression can cause profound respiratory depression. - Barbiturates: Potentiates sedative effects and increases risk of overdose. - Mono‑Mono‑Mono  ...